camlipixant + rifampin

This is a **combination drug** of **camlipixant** and **rifampin**. - **Camlipixant** is an orally administered small molecule, acting as a highly selective and potent antagonist of the P2X3 receptor, developed primarily for the treatment of refractory chronic cough (RCC). By inhibiting the P2X3 receptor—a purinergic receptor found on airway sensory nerves and activated by extracellular ATP—camlipixant reduces the neuronal hyperresponsiveness associated with persistent cough, especially in patients with high baseline cough frequency. - **Rifampin** is a broad-spectrum antibiotic of the rifamycin class, commonly used to treat tuberculosis and other bacterial infections. It acts primarily by inhibiting DNA-dependent RNA polymerase in susceptible microorganisms, suppressing RNA synthesis and bacterial replication. No products or clinical development programs were found that combine these two drugs as a fixed-dose or co-packaged regimen; any combination is likely for investigative pharmacokinetic or drug-drug interaction purposes.

Other names

camlipixant + rifampin